



RECEIVED
NOV 0 3 2002
TECH CENTER 1600/2900

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known	
		Application Number	09/663.600
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	September 15, 2000
		First Named Inventor	DUMAS MILNE EDWARDS. et al.
		Group Art Unit	1646
		Examiner Name	Eileen B. O'Hara
		Attorney Docket Number	G-031US03CIP
Sheet	2	of	3

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
EAA	J	FURUSE, et al.; "Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin"; The Journal of Cell Biology, Vol. 141, No. 7, June 29, 1998, pp. 1539-1550; The Rockefeller University Press, 0021-9525/98/06/1539/12	
	K	FURUSE, et al.; "Manner of Interaction of Heterogeneous Claudin Species Within and Between Tight Junction Strands"; The Journal of Cell Biology, Vol. 147, No. 4, November 15, 1999, pp. 891-903; The Rockefeller University Press, 0021-9525/99/11/891/13	
	L	KATAHIRA, et al.; "Molecular Cloning and Functional Characterization of the Receptor for Clostridium perfringens Enterotoxin"; The Journal of Cell Biology, Vol. 136, No. 6, March 24, 1997, pp. 1239-1247; The Rockefeller University Press, 0021-9525/97/03/1239/9	
	M	KINUGASA, et al.; "Claudins Regulate the Intestinal Barrier in Response to Immune Mediators"; Gastroenterology 2000; Vol. 118; pp. 1001-1011; The American Gastroenterological Association; 0016-5085/00	
	N	LIPPOLDT, et al.; "Organization of choroid plexus epithelial and endothelial cell tight junctions and regulations of claudin-1, -2 and -5 expression by protein kinase C"; Molecular Neuroscience, NeuroReport, Vol. 11, No. 7, pp. 1427-1431, May 15, 2000; Lippincott Williams & Wilkins, 0959-4965	
	O	LOCKHART, et al.; "Expression monitoring by hybridization to high-density oligonucleotide arrays"; Research Article; Nat Biotechnol. 14(13):1675-80; Published Dec 1996; XP-002074420	
	P	TASHIRO, et al.; "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type 1 Membrane Proteins"; Science, Vol. 261, July 30, 1993; pp.600-603; XP-000673204	
	Q	YOKOYAMA-KOBAYASHI, et al.; "A signal sequence detection system using secreted protease activity as an indicator"; Gene, Vol. 163 (1995), pp. 193-196; Elsevier Science B.V.; SSDI 0378-1119(95)00322-3	
	R	Accession No. AAG17984; Claudin-2, Homo Sapiens, Database: Genbank; GU, J.R., et al.; submitted August 1999; "Novel human cDNA clone with function of inhibiting cancer cell growth"; Unpublished	
	S	Accession No. AAC27079; Claudin-2, Mus musculus; Database: Genbank; FURUSE, et al.; submitted June 15, 1998; "Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin"; J. Cell Biol. 141 (7), 1539-1550 (1998)	
	T	Accession No. T03538; Bento Soares Homo sapiens cDNA clone IB43; Database: EMBL; SIKELA, J.M.; submitted September 21, 1992	

Examiner Signature	Eileen B. O'Hara	Date Considered	1/23/03
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

NOV 0 2 2002

TECH GEN

PTO/SB/08B (10-01)

Approved for use through 12/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/663,600
Sheet 3 of 3		Filing Date	September 15, 2000
		First Named Inventor	DUMAS MILNE EDWARDS, et al.
		Group Art Unit	1646
		Examiner Name	Eileen B. O'Hara
		Attorney Docket Number	G-031US03CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
EA	U	Accession No. AA057573; Homo sapiens cDNA clone IMAGE:381523; Database: EMBL; WILSON; submitted September 6, 1996	
EA	V	Accession No. N57409; Homo sapiens cDNA clone IMAGE:258726; Database: EMBL; WILSON; submitted February 22, 1996	
	W		
	X		
	Y		
	Z		
	AA		
	AB		

Examiner Signature	Eileen B. O'Hara	Date Considered	11/24/03
--------------------	------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/663,600
Filing Date	September 15, 2000
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	1646
Examiner Name	Eileen B. O'Hara
Attorney Docket Number	G-031US03CIP

Sheet	1	of	1
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EPA	R1	INTRONA, M. and GOLAY, J., "How can oncogenic transcription factors cause cancer: a critical review of the myb story" <i>Leukemia</i> (1999), 13:1301-1306; Stockton Press	
EPA	R2	WARD, A.C. et al., "Regulation of granulopoiesis by transcription factors and cytokine signals" <i>Leukemia</i> (2000), 14:973-990; Macmillan Publishers, Ltd.	
EPA	R3	STEWART, G., "The membrane defect in hereditary stomatocytosis", <i>Baillière's Clinical Haematology</i> (1993), 6(2):371-99; Baillière's Tindall	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	Eileen B. O'Hara	Date Considered	11/24/03
--------------------	------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

File 603

Substitute for form 1449A/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		<h3 style="text-align: center;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/663,600</td> </tr> <tr> <td>Filing Date</td> <td>September 15, 2000</td> </tr> <tr> <td>First Named Inventor</td> <td>DUMAS MILNE EDWARDS, et al.</td> </tr> <tr> <td>Art Unit</td> <td>1646</td> </tr> <tr> <td>Examiner Name</td> <td>Eileen B. O'Hara</td> </tr> <tr> <td>Attorney Docket Number</td> <td>G-031US03CIP</td> </tr> </table>		Application Number	09/663,600	Filing Date	September 15, 2000	First Named Inventor	DUMAS MILNE EDWARDS, et al.	Art Unit	1646	Examiner Name	Eileen B. O'Hara	Attorney Docket Number	G-031US03CIP
Application Number	09/663,600														
Filing Date	September 15, 2000														
First Named Inventor	DUMAS MILNE EDWARDS, et al.														
Art Unit	1646														
Examiner Name	Eileen B. O'Hara														
Attorney Docket Number	G-031US03CIP														
Sheet	1	of	3												

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	us.6,022,715	02-08-2000	Marenkova et al.	A11
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	A	WO 97/07198 - A2	02/27/1997	Genetics Institute Inc.	A11	
	B	WO 98/45436 - A2	10/15/1998	Genetics Institute Inc.	A11	
	C	WO 99/06548 - A2 & A3	02/11/1999	Genset	A11	
	D	WO 99/25825 - A2	05/27/1999	Genset	A11	
	E	WO 00/12708 - A2	03/09/2000	Genentech Inc.	A11	
	F	WO 00/18915 - A2	04/06/2000	Incyte Pharmaceuticals	A11	
	G	WO 00/26360 - A1	05/11/2000	Adherex Technologies	A11	
	H					
	I					

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/663.600
Filing Date	September 15, 2000
First Named Inventor	DUMAS MILNE EDWARDS, et al.
Group Art Unit	1646
Examiner Name	Eileen B. O'Hara
Attorney Docket Number	G-031US03CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7 ²
	U	Accession No. AA057573; Homo sapiens cDNA clone IMAGE:381923; Database: EMBL; WILSON; submitted September 5, 1996	
	V	Accession No. N57409; Homo sapiens cDNA clone IMAGE:258726; Database: EMBL; WILSON; submitted February 22, 1996	
	W		
	X		
	Y		
	Z		
	AA		
	AB		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete If Known	
Application Number	09/663.600			
Filing Date	September 15, 2000			
First Named Inventor	DUMAS MILNE EDWARDS, et al.			
Group Art Unit	1646			
Examiner Name	Eileen B. O'Hara			
Attorney Docket Number	G-031US03CIP			
Sheet	2	of	3	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	J	FURUSE, et al.; "Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin"; The Journal of Cell Biology, Vol. 141, No. 7, June 29, 1998, pp. 1539-1550; The Rockefeller University Press, 0021-9525/98/06:1539/12	
	K	FURUSE, et al.; "Manner of Interaction of Heterogeneous Claudin Species Within and Between Tight Junction Strands"; The Journal of Cell Biology, Vol. 147, No. 4, November 15, 1999, pp. 891-903; The Rockefeller University Press, 0021-9525/99/11/891/13	
	L	KATAHIRA, et al.; "Molecular Cloning and Functional Characterization of the Receptor for Clostridium perfringens Enterotoxin"; The Journal of Cell Biology, Vol. 136, No. 6, March 24, 1997, pp. 1239-1247; The Rockefeller University Press, 0021-9525/97/03/1239/9	
	M	KINUGASA, et al.; "Claudins Regulate the Intestinal Barrier in Response to Immune Mediators"; Gastroenterology 2000; Vol. 118; pp. 1001-1011; The American Gastroenterological Association; 0013-0805/00	
	N	LIPPOLDT, et al.; "Organization of choroid plexus epithelial and endothelial cell tight junctions and regulations of claudin-1, -2 and -5 expression by protein kinase C"; Molecular Neuroscience, NeuroReport, Vol. 11, No. 7, pp. 1427-1431, May 15, 2000; Lippincott Williams & Wilkins, 0959-4965	
	O	LOCKHART, et al.; "Expression monitoring by hybridization to high-density oligonucleotide arrays"; Research Article; Nat Biotechnol 14(13):1675-80, Published Dec 1996; XP-002074420	
	P	TASHIRO, et al.; "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type 1 Membrane Proteins"; Science, Vol. 261, July 30, 1993; pp. 600-603; XP-000673204	
	Q	YOKOYAMA-KOBAYASHI, et al.; "A signal sequence detection system using secreted protease activity as an indicator"; Gene, Vol. 163 (1995), pp. 193-198; Elsevier Science B.V.; SSOI 0378-1119(95)00322-3	
	R	Accession No. AAC17984; Claudin-2, Homo Sapiens, Database: Genbank; GU, J.R., et al.; submitted August 1999; "Novel human cDNA clone with function of inhibiting cancer cell growth"; Unpublished	
	S	Accession No. AAC27079; Claudin-2, Mus musculus; Database: Genbank; FURUSE, et al.; submitted June 15, 1998; "Claudin-1 and -2: Novel Integral Membrane Proteins Localizing at Tight Junctions with No Sequence Similarity to Occludin"; J. Cell Biol. 141 (7), 1539-1550 (1998)	
	T	Accession No. T03538; Bento Soares Homo sapiens cDNA clone IB43; Database: EMBL; SIKELA, J.M.; submitted September 21, 1992	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.